110 related articles for article (PubMed ID: 11853121)
1. Cannabinoid-induced stimulation of motor activity in planaria through an opioid receptor-mediated mechanism.
Buttarelli FR; Pontieri FE; Margotta V; Palladini G
Prog Neuropsychopharmacol Biol Psychiatry; 2002 Jan; 26(1):65-8. PubMed ID: 11853121
[TBL] [Abstract][Full Text] [Related]
2. Agmatine: identification and inhibition of methamphetamine, kappa opioid, and cannabinoid withdrawal in planarians.
Rawls SM; Gerber K; Ding Z; Roth C; Raffa RB
Synapse; 2008 Dec; 62(12):927-34. PubMed ID: 18792993
[TBL] [Abstract][Full Text] [Related]
3. Behavioral sensitization to heroin by cannabinoid pretreatment in the rat.
Pontieri FE; Monnazzi P; Scontrini A; Buttarelli FR; Patacchioli FR
Eur J Pharmacol; 2001 Jun; 421(3):R1-3. PubMed ID: 11516439
[TBL] [Abstract][Full Text] [Related]
4. An NMDA antagonist (LY 235959) attenuates abstinence-induced withdrawal of planarians following acute exposure to a cannabinoid agonist (WIN 55212-2).
Rawls SM; Gomez T; Raffa RB
Pharmacol Biochem Behav; 2007 Mar; 86(3):499-504. PubMed ID: 17306870
[TBL] [Abstract][Full Text] [Related]
5. Opioid-dopamine interaction in planaria: a behavioral study.
Passarelli F; Merante A; Pontieri FE; Margotta V; Venturini G; Palladini G
Comp Biochem Physiol C Pharmacol Toxicol Endocrinol; 1999 Sep; 124(1):51-5. PubMed ID: 10579648
[TBL] [Abstract][Full Text] [Related]
6. Effects of the cannabinoid receptor agonist WIN 55,212-2 on operant behavior and locomotor activity in rats.
Drews E; Schneider M; Koch M
Pharmacol Biochem Behav; 2005 Jan; 80(1):145-50. PubMed ID: 15652390
[TBL] [Abstract][Full Text] [Related]
7. Modulation of the cardiac autonomic transmission of pithed rats by presynaptic opioid OP4 and cannabinoid CB1 receptors.
Malinowska B; Piszcz J; Koneczny B; Hryniewicz A; Schlicker E
Naunyn Schmiedebergs Arch Pharmacol; 2001 Sep; 364(3):233-41. PubMed ID: 11521166
[TBL] [Abstract][Full Text] [Related]
8. Antitussive effect of WIN 55212-2, a cannabinoid receptor agonist.
Morita K; Kamei J
Eur J Pharmacol; 2003 Aug; 474(2-3):269-72. PubMed ID: 12921873
[TBL] [Abstract][Full Text] [Related]
9. Involvement of the cannabinoid CB1 receptor in the opioid inhibition of the response to cholecystokinin and acute withdrawal response.
Romanelli L; Palmery M; Tucci P; Amico MC; Morrone LA; Valeri P
Neurotoxicology; 2005 Oct; 26(5):819-27. PubMed ID: 15913779
[TBL] [Abstract][Full Text] [Related]
10. Ultra-low dose naltrexone enhances cannabinoid-induced antinociception.
Paquette J; Olmstead MC
Behav Pharmacol; 2005 Dec; 16(8):597-603. PubMed ID: 16286810
[TBL] [Abstract][Full Text] [Related]
11. Modulation of paraoxon toxicity by the cannabinoid receptor agonist WIN 55,212-2.
Nallapaneni A; Liu J; Karanth S; Pope C
Toxicology; 2006 Oct; 227(1-2):173-83. PubMed ID: 16956707
[TBL] [Abstract][Full Text] [Related]
12. A nitric oxide synthase inhibitor (L-NAME) attenuates abstinence-induced withdrawal from both cocaine and a cannabinoid agonist (WIN 55212-2) in Planaria.
Rawls SM; Rodriguez T; Baron DA; Raffa RB
Brain Res; 2006 Jul; 1099(1):82-7. PubMed ID: 16782070
[TBL] [Abstract][Full Text] [Related]
13. Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice.
McMahon LR; Koek W
Eur J Pharmacol; 2007 Aug; 569(1-2):70-6. PubMed ID: 17553486
[TBL] [Abstract][Full Text] [Related]
14. Role of cannabinoid CB1 receptors and Gi/o protein activation in the modulation of synaptosomal Na+,K+-ATPase activity by WIN55,212-2 and delta(9)-THC.
Araya KA; David Pessoa Mahana C; González LG
Eur J Pharmacol; 2007 Oct; 572(1):32-9. PubMed ID: 17644088
[TBL] [Abstract][Full Text] [Related]
15. Central effects of the cannabinoid receptor agonist WIN55212-2 on respiratory and cardiovascular regulation in anaesthetised rats.
Pfitzer T; Niederhoffer N; Szabo B
Br J Pharmacol; 2004 Jul; 142(6):943-52. PubMed ID: 15226190
[TBL] [Abstract][Full Text] [Related]
16. Cannabinoids inhibit excitatory inputs to neurons in the shell of the nucleus accumbens: an in vivo electrophysiological study.
Pistis M; Muntoni AL; Pillolla G; Gessa GL
Eur J Neurosci; 2002 Jun; 15(11):1795-802. PubMed ID: 12081659
[TBL] [Abstract][Full Text] [Related]
17. Long-lasting increase of alcohol relapse by the cannabinoid receptor agonist WIN 55,212-2 during alcohol deprivation.
López-Moreno JA; González-Cuevas G; Rodríguez de Fonseca F; Navarro M
J Neurosci; 2004 Sep; 24(38):8245-52. PubMed ID: 15385608
[TBL] [Abstract][Full Text] [Related]
18. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation.
Ramírez BG; Blázquez C; Gómez del Pulgar T; Guzmán M; de Ceballos ML
J Neurosci; 2005 Feb; 25(8):1904-13. PubMed ID: 15728830
[TBL] [Abstract][Full Text] [Related]
19. Cannabinoid receptor and WIN 55 212-2-stimulated [35S]-GTPgammaS binding in the brain of mu-, delta- and kappa-opioid receptor knockout mice.
Berrendero F; Mendizábal V; Murtra P; Kieffer BL; Maldonado R
Eur J Neurosci; 2003 Oct; 18(8):2197-202. PubMed ID: 14622180
[TBL] [Abstract][Full Text] [Related]
20. The cannabinoid agonists WIN 55,212-2 and CP 55,940 attenuate rotational behavior induced by a dopamine D1 but not a D2 agonist in rats with unilateral lesions of the nigrostriatal pathway.
Anderson LA; Anderson JJ; Chase TN; Walters JR
Brain Res; 1995 Sep; 691(1-2):106-14. PubMed ID: 8590042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
